AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9704782 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in fat mass
Number of subjects: 16
Study 9704782 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in basal VO2
Number of subjects: 16
Study 7641363 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 12
Study 7641363 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg
Number of subjects: 12
Study 7641363 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-Captopril combination
Number of subjects: 12
Study 2238185 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 12 mg once daily
Number of subjects: 266
Study 2238185 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine 20 mg once daily
Number of subjects: 266
Study 2238185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorthiazide 12.5 mg daily (as a supplement to spirapril)
Number of subjects: 266
Study 2238185 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorthiazide (as a supplement to nitrendipine)
Number of subjects: 266
Study 356658 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 1%
Number of subjects: 13
Study 356658 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 2%
Number of subjects: 13
Study 356658 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 4%
Number of subjects: 13
Study 356658 — intervention group
Group type: COMPARATOR
Intervention: Untreated eyes
Number of subjects: 13
Study 356658 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (all concentrations)
Number of subjects: 13
Study 31215156 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% Timosaponin A-III (TA-III)
Number of subjects: 21
Study 31580781 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (Versawave, Hoya ConBio, San Francisco, CA; 40 hz, 50 mJ/pulse)
Number of subjects: 5
Study 31580781 — intervention group
Group type: COMPARATOR
Intervention: Scalpel (control site)
Number of subjects: 5
Study 27925437 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month WLM program (WL + WLM; n = 47)
Number of subjects: 92
Study 27925437 — intervention group
Group type: COMPARATOR
Intervention: No resources (WL-only; n = 45)
Number of subjects: 92
Study 26277033 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 30
Study 26277033 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 30
Study 26277033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24686345 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track (FT) rehabilitation program
Number of subjects: 52
Study 24686345 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC) program
Number of subjects: 52
Study 22444187 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 24
Study 22444187 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 24
Study 22444187 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone pretreatment
Number of subjects: 24
Study 22444187 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline pretreatment
Number of subjects: 24
Study 19240066 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-DES
Number of subjects: 1007
Study 19240066 — intervention group
Group type: COMPARATOR
Intervention: SES
Number of subjects: 1007
Study 19240066 — intervention group
Group type: COMPARATOR
Intervention: ZES
Number of subjects: 1007
Study 17827503 — intervention group
Group type: EXPERIMENTAL
Intervention: rescue angioplasty (rPCI) in MERLIN trial
Number of subjects: 0
Study 15450054 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of antipsychotic medications
Number of subjects: 30
Study 15450054 — intervention group
Group type: COMPARATOR
Intervention: Continued treatment with antipsychotic medications
Number of subjects: 30
Study 11588698 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin 50 mg/day
Number of subjects: 0
Study 11588698 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin 70 mg/day
Number of subjects: 0
Study 11588698 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B 0.5 mg/kg/day
Number of subjects: 0
Study 11588698 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 0
Study 9679876 — intervention group
Group type: EXPERIMENTAL
Intervention: Filiform dilation
Number of subjects: 210
Study 9679876 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal urethrotomy
Number of subjects: 210
Study 9679876 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dilation or urethrotomy
Number of subjects: 210
Study 9679876 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dilation or urethrotomy
Number of subjects: 210
Study 7916274 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise stress echocardiography
Number of subjects: 136
Study 7916274 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography
Number of subjects: 136
Study 7916274 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole stress echocardiography
Number of subjects: 136
Study 7916274 — intervention group
Group type: COMPARATOR
Intervention: Control group (beta-blocker therapy)
Number of subjects: 136
Study 2688346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg IV every 6 hours for 8 days)
Number of subjects: 25
Study 2688346 — intervention group
Group type: COMPARATOR
Intervention: No ranitidine (control group)
Number of subjects: 25
Study 472340 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg 15‐methyl‐PGF2 alpha methyl ester
Number of subjects: 16
Study 472340 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg 15‐methyl‐PGF2 alpha methyl ester
Number of subjects: 16
Study 472340 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of 15‐methyl‐PGF2 alpha methyl ester
Number of subjects: 16
Study 472340 — intervention group
Group type: COMPARATOR
Intervention: Nonpregnant patients
Number of subjects: 16
Study 472340 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 16
Study 30878222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (150-200 μg/kg) and albendazole (400 mg) plus five further doses of ivermectin alone at 3-week intervals over 18 weeks
Number of subjects: 2712
Study 30878222 — intervention group
Group type: COMPARATOR
Intervention: Control group received single oral doses of ivermectin (150-200 μg/kg) and albendazole (400 mg) without further doses of ivermectin
Number of subjects: 2712
Study 30878222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (intervention group)
Number of subjects: 2712
Study 30878222 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2712
Study 28057693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 2004
Study 28057693 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2004
Study 26336866 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management services
Number of subjects: 44
Study 26336866 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 44
Study 23338110 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 8.0 mg + clonidine 75 µg + morphine 100 µg
Number of subjects: 66
Study 23338110 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 10 mg + clonidine 75 µg + morphine 100 µg
Number of subjects: 66
Study 20625342 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia therapy (32.5°C) for 24 hours, started within 8 hours of injury and rewarming at a rate of 0.5°C every 2 hours
Number of subjects: 27
Study 20625342 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (37.0°C)
Number of subjects: 27
Study 20625342 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum GFAP measured on day 1 post-TBI
Number of subjects: 27
Study 20625342 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum GFAP cutoff level of 0.6 ng/mL
Number of subjects: 27
Study 20625342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid GFAP
Number of subjects: 27
Study 20625342 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum GFAP
Number of subjects: 27
Study 20625342 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curves for pediatric intensive care unit day 1 serum GFAP
Number of subjects: 27
Study 19759431 — intervention group
Group type: EXPERIMENTAL
Intervention: Background music prior to attention test
Number of subjects: 32
Study 19759431 — intervention group
Group type: EXPERIMENTAL
Intervention: Background music during attention test
Number of subjects: 32
Study 19759431 — intervention group
Group type: COMPARATOR
Intervention: No background music
Number of subjects: 32
Study 18025525 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg bid voriconazole
Number of subjects: 34
Study 18025525 — intervention group
Group type: COMPARATOR
Intervention: 400 mg qd efavirenz
Number of subjects: 34
Study 14987322 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg b.d. plus dietary treatment
Number of subjects: 36
Study 14987322 — intervention group
Group type: COMPARATOR
Intervention: Dietary treatment alone
Number of subjects: 36
Study 11601952 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality indicators for the management of heart failure
Number of subjects: 0
Study 9270067 — intervention group
Group type: EXPERIMENTAL
Intervention: Acentrally active drug that enhances AMPA receptor‐mediated currents
Number of subjects: 0
Study 8417487 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical techniques (bilateral vagotomy plus Heineke‐Mikulicz pyloroplasty, bilateral truncal vagotomy plus anterior pylorectomy, proximal gastric vagotomy, antrectomy and Billroth I reconstruction, and antrectomy and Billroth II reconstruction)
Number of subjects: 50
Study 8417487 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 50
Study 8417487 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 50
Study 8417487 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between 99mTc‐HIDA and bile acids
Number of subjects: 50
Study 3535551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwoven, disposable gown and drape fabrics
Number of subjects: 0
Study 3535551 — intervention group
Group type: COMPARATOR
Intervention: Reusable cotton poplin
Number of subjects: 0
Study 3535551 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (nonwoven and reusable fabrics)
Number of subjects: 0
Study 11733393 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 0
Study 11733393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30742718 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal asthma
Number of subjects: 1579263
Study 30742718 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal asthma
Number of subjects: 1579263
Study 30742718 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal asthma among paternal half-siblings
Number of subjects: 1579263
Study 30742718 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal asthma among full-cousins
Number of subjects: 1579263
Study 30742718 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal asthma among half-cousins
Number of subjects: 1579263
Study 30742718 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to asthma medications among mothers with asthma
Number of subjects: 1579263
Study 28629282 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious trauma‐writing condition
Number of subjects: 105
Study 28629282 — intervention group
Group type: COMPARATOR
Intervention: Conventional trauma‐writing condition
Number of subjects: 105
Study 24747626 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (GTN) patches applied once a day
Number of subjects: 40
Study 24747626 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 40
Study 23285271 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet Support Group (ISG)
Number of subjects: 0
Study 23285271 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Internet Training Program (ITP)
Number of subjects: 0
Study 23285271 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ISG and ITP (ITP+ISG)
Number of subjects: 0
Study 23285271 — intervention group
Group type: COMPARATOR
Intervention: Control website with delayed access to e-couch
Number of subjects: 0
Study 20584114 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (10 mg diluted in 10 mL of distilled water daily, N=37)
Number of subjects: 86
Study 20584114 — intervention group
Group type: COMPARATOR
Intervention: Control (10 mL of saline water, N=37)
Number of subjects: 86
Study 17356786 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable medication dosing
Number of subjects: 228
Study 17356786 — intervention group
Group type: COMPARATOR
Intervention: Fixed medication dosing
Number of subjects: 228
Study 15365685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous citalopram (10 mg, 20 mg, 40 mg, 0.33 mg/kg)
Number of subjects: 75
Study 15365685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 12166339 — intervention group
Group type: EXPERIMENTAL
Intervention: Incadronate (10 mg intravenous infusion)
Number of subjects: 26
Study 12166339 — intervention group
Group type: COMPARATOR
Intervention: Elcatonin (40 IU intramuscular injections twice daily for 7 days)
Number of subjects: 26
Study 10439722 — intervention group
Group type: EXPERIMENTAL
Intervention: Punitive damage caps
Number of subjects: 0
Study 10439722 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifurcation of compensatory and punitive damage decisions
Number of subjects: 0
Study 7791151 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate 3.0 g/day (titrated to 3.55 g/day)
Number of subjects: 301
Study 7791151 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg/day (titrated to 112 mg/day)
Number of subjects: 301
Study 7791151 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate
Number of subjects: 301
Study 7791151 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 301
Study 1983322 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine b.d.
Number of subjects: 325
Study 1983322 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine nocte
Number of subjects: 325
Study 1983322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 583489 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation A (Digacin)
Number of subjects: 19
Study 583489 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation B
Number of subjects: 19
Study 583489 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation C
Number of subjects: 19
Study 583489 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation D
Number of subjects: 19
Study 583489 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration
Number of subjects: 19
Study 30423462 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory stress (Salmonella typhi vaccine)
Number of subjects: 39
Study 30423462 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress (Trier Social Stress Test)
Number of subjects: 39
Study 30423462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 28467857 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR; 2.4 ± 0.2 h of sleep)
Number of subjects: 7
Study 28467857 — intervention group
Group type: COMPARATOR
Intervention: Control (CON; 7.1 ± 0.3 h of sleep)
Number of subjects: 7
Study 26506050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 203
Study 26506050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 24352094 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% carbohydrate (CHO) solution (700 mL)
Number of subjects: 22
Study 24352094 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0% CHO) (700 mL)
Number of subjects: 22
Study 20629764 — intervention group
Group type: EXPERIMENTAL
Intervention: DECISION+ intervention (experimental group)
Number of subjects: 492
Study 20629764 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed DECISION+)
Number of subjects: 492
Study 19835121 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspended moxibustion on temperature-sensitive acupoints plus herbal enema
Number of subjects: 60
Study 19835121 — intervention group
Group type: COMPARATOR
Intervention: Moxibustion at Guanyuan (CV 4), Zhongji (CV 3), Shenshu (BL 23) combined with herbal enema
Number of subjects: 60
Study 18246965 — intervention group
Group type: EXPERIMENTAL
Intervention: 9% hydrogen peroxide gel (Colgate Visible White)
Number of subjects: 46
Study 18246965 — intervention group
Group type: COMPARATOR
Intervention: 20% carbamide peroxide gel (Opalescence)
Number of subjects: 46
Study 15358464 — intervention group
Group type: COMPARATOR
Intervention: Human Tubal Fluid (HTF)
Number of subjects: 109
Study 15358464 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation Stage One (P1)
Number of subjects: 109
Study 11410799 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 microg/kg G‐CSF (lenograstim) when grade 3 leukopenia or neutropenia appeared (Group 1)
Number of subjects: 68
Study 11410799 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 microg/kg G‐CSF (lenograstim) when grade 3 leukopenia or neutropenia appeared (Group 2)
Number of subjects: 68
Study 11410799 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 microg/kg G‐CSF (lenograstim) when grade 2 leukopenia or neutropenia appeared (Group 3)
Number of subjects: 68
Study 9534714 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated radiotherapy protocols
Number of subjects: 0
Study 9534714 — intervention group
Group type: COMPARATOR
Intervention: British Institute of Radiology's trials
Number of subjects: 0
Study 9534714 — intervention group
Group type: COMPARATOR
Intervention: Recent studies
Number of subjects: 0
Study 8328239 — intervention group
Group type: EXPERIMENTAL
Intervention: Aylesbury spatula
Number of subjects: 14172
Study 8328239 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolon spatula
Number of subjects: 14172
Study 8328239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervex device
Number of subjects: 14172
Study 8328239 — intervention group
Group type: EXPERIMENTAL
Intervention: Aylesbury spatula with Cytobrush
Number of subjects: 14172
Study 8328239 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14172
Study 3113331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg) given twice a day for 2 days
Number of subjects: 118
Study 3113331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 30881050 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol nasal solution
Number of subjects: 73
Study 30881050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 28408039 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular visual function tests (Esterman VF score, binocular VA)
Number of subjects: 607
Study 28408039 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular VA
Number of subjects: 607
Study 28408039 — intervention group
Group type: EXPERIMENTAL
Intervention: VAQ
Number of subjects: 607
Study 28408039 — intervention group
Group type: EXPERIMENTAL
Intervention: Better-eye, average-eye, and binocular summation of VA
Number of subjects: 607
Study 28408039 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular VF testing
Number of subjects: 607
Study 25647746 — intervention group
Group type: EXPERIMENTAL
Intervention: Different position ventilation group (n=34)
Number of subjects: 67
Study 25647746 — intervention group
Group type: COMPARATOR
Intervention: Supine position ventilation group (n=33)
Number of subjects: 67
Study 25647746 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study 22766389 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drink (25 g)
Number of subjects: 20
Study 22766389 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (30 mg saccharine)
Number of subjects: 20
Study 21486921 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline vitamin E concentrations
Number of subjects: 148
Study 21486921 — intervention group
Group type: EXPERIMENTAL
Intervention: Time‐varying vitamin E concentrations
Number of subjects: 148
Study 18645322 — intervention group
Group type: EXPERIMENTAL
Intervention: FES + exercise
Number of subjects: 26
Study 18645322 — intervention group
Group type: COMPARATOR
Intervention: exercise-only
Number of subjects: 26
Study 17031805 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 20
Study 17031805 — intervention group
Group type: COMPARATOR
Intervention: Placebo stretching (PS)
Number of subjects: 20
Study 12721240 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (4 g orally, twice a day for 2 weeks)
Number of subjects: 129
Study 12721240 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 g orally, twice a day for 2 weeks)
Number of subjects: 129
Study 12721240 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 129
Study 12721240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 12721240 — intervention group
Group type: COMPARATOR
Intervention: Glutamine and Placebo
Number of subjects: 129
Study 10570413 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised 1997 TNM staging system
Number of subjects: 677
Study 10570413 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I
Number of subjects: 677
Study 10570413 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IIA
Number of subjects: 677
Study 10570413 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IIB
Number of subjects: 677
Study 10570413 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III
Number of subjects: 677
Study 10570413 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IVA
Number of subjects: 677
Study 10570413 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IVB
Number of subjects: 677
Study 10570413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial nerve involvement
Number of subjects: 677
Study 10570413 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbit involvement
Number of subjects: 677